Company intelligence / Profile preview

Velomedix

Menlo Park, California, United Statespmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Employees: ~2
Development stage: Commercial

Overview

Velomedix developed a proprietary medical device platform capable of rapidly inducing mild therapeutic hypothermia in under 15 minutes—significantly faster than existing technologies—to improve outcomes in patients with cardiac arrest and acute myocardial infarction. Early clinical results from the CAMARO trial showed unprecedented positive neurologic outcomes post-cardiac arrest compared to published data. The VELOCITY pilot study was launched to further evaluate safety and feasibility in heart attack patients, but the company did not reach commercialization before ceasing operations.

Therapeutic areas: CardiovascularNeurology
Modalities: Device
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on Velomedix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Velomedix.

Explore the full profile